Sep 02, 2020 10:18 JST

Source: Fujitsu Ltd

Fujitsu and Tokyo Shinagawa Hospital Embark on Joint Research and Development of AI Technology to Support Diagnosis of COVID-19 Pneumonia

News Facts:

- Fujitsu and Tokyo Shinagawa Hospital to develop an AI-based technology to facilitate the diagnosis of COVID-19 pneumonia
- The new AI technology will learn from past CT scans of COVID-19 pneumonia patients, reducing the burden on doctors making diagnoses
- Fujitsu will consider future commercialization of this technology for broader medical applications

TOKYO, Sep 02, 2020 - (JCN Newswire) - Fujitsu and Tokyo Shinagawa Hospital today announced the launch of a joint R&D project for AI technology to support diagnostic imaging via chest CT (Computed Tomography), which represents a promising candidate for the effective diagnosis of COVID-19 pneumonia.

Figure 1: Envisioned flow of novel coronavirus infection testing (AI diagnostic imaging developed through this joint R&D effort)

The newly-proposed technology supports doctors performing diagnostic imaging on patients suspected of having COVID-19 pneumonia, presenting the likelihood of infection through a numerical, three-dimensional visualization of the spread of shadows in the lungs using chest CT imaging. Applying AI to this analysis could significantly reduce the burden on doctors who diagnose COVID-19 pneumonia by automating a process that normally demands the visual confirmation of hundreds of chest CT images per patient.

Fujitsu and Tokyo Shinagawa Hospital anticipate that the system will deliver early detection of cases of COVID-19 pneumonia based on chest CT image findings, even in cases in which the possibility of infection is determined to be low upon initial examination.

This joint research will enhance AI diagnostic support technology for novel coronavirus pneumonia, and Fujitsu ultimately aims to commercialize the technology as a healthcare solution for frontline medical professionals.


When treating patients who are strongly suspected of having a novel coronavirus infection, the diagnosis and treatment plan are determined holistically based on PCR test results as well as other test results including blood tests and chest CT test (Figure 1). Even if the PCR test is negative, the diagnosis of new-onset coronavirus pneumonia can be made by other tests, and imaging with chest CT is an important consideration.

Doctors make lung disease diagnoses based on the characteristics of the shadows in the lesion on the patient's chest CT image. In addition to identifying abnormalities, they visually check hundreds of chest CT images per patient to understand the three-dimensional distribution of shadows throughout the lung. A growing demand for technologies that reduce the burden on doctors and support speedy decision-making has accompanied the spread of the COVID-19 virus. It is also important to identify novel coronavirus pneumonia from a CT scan of the patient's chest if there is a low likelihood of a novel coronavirus infection during the examination and PCR testing is not performed.

In response to the need for diagnostic support, Fujitsu and Tokyo Shinagawa Hospital will jointly embark on the development of AI-assisted diagnostic imaging technology for chest CT scans, which are considered to be an effective method in diagnosing novel coronavirus pneumonia.

About the joint development of AI imaging support technology

Past CT image data of COVID-19 pneumonia patients from Tokyo Shinagawa Hospital will aid in the development of AI technology that detects abnormal shadow patterns in the lungs. As the AI learns from this data about the possibility of COVID-19 pneumonia, Fujitsu and Tokyo Shinagawa Hospital will work together to evaluate the effectiveness of the technology.

When diagnosing COVID-19 pneumonia, patterns of abnormal opacities in the lungs as well as the spread of shadows across the entire lung is important information.

Patterns of abnormal shadows are detected using AI developed by Fujitsu Laboratories, Ltd. The lung is divided into four areas on the CT image: the right lung periphery, the right lung center, the left lung center, and the left lung periphery. The distribution of shadows in the vertical direction in each area is displayed in a histogram(1). This will enable the development of new AI that can quantify the three-dimensional spread of shadows, while using the detected abnormal shadow patterns and shadow distributions to identify COVID-19 pneumonia.

While showing the possibility of COVID-19 infection with the AI technology, the aim is to shorten the amount of time doctors spend visually confirming the three-dimensional spread of the shadow from hundreds of chest CT images and to allow even non-specialists to efficiently diagnose COVID-19 pneumonia.

Future Plans

Through this joint research and development, Fujitsu and Tokyo Shinagawa Hospital aim to deliver technology that leverages a variety of information for diagnosis of COVID-19 pneumonia to achieve improved diagnostic support from chest CT image diagnosis.

Fujitsu is considering the commercialization of this technology as a healthcare solution. By linking it with electronic medical record information, the goal is to support diagnosis by doctors based on chest CT images, while also expanding the application area of this technology.

Tokyo Shinagawa Hospital aims to contribute to society by integrating various studies conducted in the hospital and using them for diagnosis and treatment of novel coronavirus pneumonia.

(1) Histogram
A type of statistical graph that enables visual recognition of data distribution conditions.

About Fujitsu Ltd
Fujitsu is the leading Japanese information and communication technology (ICT) company offering a full range of technology products, solutions and services. Approximately 130,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.9 trillion yen (US$35 billion) for the fiscal year ended March 31, 2020. For more information, please see

Source: Fujitsu Ltd
Sectors: Enterprise IT, BioTech, AI

Copyright ©2020 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Fujitsu and SNP Announce Global Platinum Partnership Agreement -- Accelerating SAP S/4HANA Conversion Business with Advanced Data Transformation Technologies
September 24 2020 13:55 JST
Fujitsu to Deliver New Supercomputer System for Canon
September 23 2020 09:25 JST
Fujitsu Develops Technology to Block Facial Authentication Fraud
September 18 2020 09:20 JST
Fujitsu and Toyota Systems Optimize Large-Scale Supply Chain Logistics using Quantum-Inspired Technology
September 10 2020 10:34 JST
Fujitsu Expands Potential of Automotive Big Data with Launch of AI-Powered, On-Vehicle Camera Video Analysis Platform, "Fujitsu Future Mobility Accelerator Digital Twin Analyzer"
September 10 2020 10:14 JST
Fujitsu to Reimagine the Future at Fujitsu ActivateNow 2020 Global Digital Experience
September 01 2020 09:16 JST
Fujitsu Concludes Share Transfer Agreement Concerning the Mobile Phone Retail Store Business
August 31 2020 15:35 JST
Fujitsu Named "DX Company" for 2020
August 25 2020 14:56 JST
Fujitsu Optimizes Evacuation Center Management to Mitigate COVID-19 Risk with AI in Joint Field Trial in City of Kawasaki
August 24 2020 10:47 JST
Fujitsu Reimagines Path to Post-Covid Prosperity with Global Initiative
August 20 2020 15:06 JST
More Press release >>

Latest Press Release

More Latest Release >>